初始降尿酸药物剂量与成年男性痛风患者痛风发作的关联
该单中心队列研究纳入2017年8月至2020年10月的582例痛风患者,采用Cox风险模型联合IPTW分析初始非布司他剂量与6周内痛风发作的关联。结果显示,初始低剂量非布司他单药与秋水仙碱预防相比痛风发作风险无统计学显著差异(HR 1.26;95%CI 0.58, 2.72),而初始高剂量非布司他与痛风发作风险升高相关(HR 3.08;95%CI 1.34, 7.07)。
要点
- 6周随访期间71例(12.2%)患者出现痛风发作。
- 初始低剂量非布司他单药与秋水仙碱预防的痛风发作风险无统计学显著差异(HR 1.26;95%CI 0.58, 2.72)。
- 初始高剂量非布司他与痛风发作风险升高相关(HR 3.08;95%CI 1.34, 7.07)。
核心结论
- 初始低剂量非布司他在预防痛风发作方面与秋水仙碱预防同等有效,而初始高剂量非布司他单药与痛风发作风险升高相关。
研究设计与样本
- 单中心队列研究,连续纳入2017年8月至2020年10月的痛风患者,采用标准问卷收集人口学与临床信息并同日检测生化指标,使用Cox风险模型联合IPTW分析。
主要发现
- 共纳入582例痛风患者,6周随访期间71例(12.2%)出现痛风发作。
- 与秋水仙碱预防相比,初始低剂量非布司他单药的痛风发作风险无统计学显著差异(HR 1.26;95%CI 0.58, 2.72)。
- 与秋水仙碱预防相比,初始高剂量非布司他的痛风发作风险升高(HR 3.08;95%CI 1.34, 7.07)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Frequent gout attacks in the initial introduction of urate-lowering therapy (ULT) are significant causes of poor drug adherence and ULT discontinuation. Initial low-dose urate-lowering drugs may be effective in reducing gout flares, however robust evidence is sparse. The aim of this study was therefore to assess the association of initial dose urate-lowering drugs with gout flares in adult males with gout during the initial introduction of ULT. METHODS: This cohort study obtained data on consecutive gout patients from a single-centre gout cohort study from August 2017 to October 2020. A standard questionnaire was applied to collect demographic and clinical information, and biochemical parameters were tested on the same day. The primary endpoint was to estimate the association of initial dose febuxostat with gout flares, using Cox hazard models with inverse probability of treatment weighting (IPTW). RESULTS: A total of 582 gout patients were included in this study. During the 6-week follow-up, 71 (12.2%) patients suffered gout flares. In the main analysis using Cox hazard models with IPTW, compared with colchicine prophylaxis, initial low-dose febuxostat alone had no statistical significance with the increased risk of gout flares [hazard ratio (HR) 1.26; 95% CI 0.58, 2.72], while initial high-dose febuxostat was associated with an increased risk of gout flares (HR 3.08; 95% CI 1.34, 7.07). CONCLUSIONS: This observational study demonstrated that initial low-dose febuxostat was equally effective in preventing gout flares as colchicine prophylaxis, while initial high-dose febuxostat alone was associated with an increased risk of gout flares.
引用
- Li X, Shao Q, Shen J, et al. Association between the initial dose urate-lowering drugs and gout flares in adult males with gout. Rheumatology (Oxford). 2024. PMID: 37610331. doi:10.1093/rheumatology/kead437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。